healthy individual – Page 6 – Communicable Diseases Research

Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021

2021년 5월에 SARS-CoV-2에 면역된 폴란드 인구의 숨겨진 부분

Research Article

Published on 2022-02-032022-09-12
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단,

Cardiac Arrest and Hypoxic-Ischemic Encephalopathy Following an Emergency Caesarean Section in a COVID-19 Patient

Obstetrics/Gynecology

Published on 2022-02-032022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] acute respiratory syndrome Admission arrest bradycardia cardiac cardiorespiratory arrest catastrophic chest pain circulation clinically Coma Complication consequence coronavirus coronavirus disease coronavirus in pregnancy COVID-19 COVID-19 in pregnancy COVID-19 infection COVID-19 vaccination death discharged home distress Dyspnea Emergency Encephalopathy expired fetal gravid Health healthy individual highlight Hospitalized hypoxic Infection medical condition much higher nine Patient Pneumonia positive prenatal remained required Respiratory failure risk sar-cov-2 infection SARS-CoV-2 sars-cov-2 during pregnancy Section severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suffered supplemental oxygen the patient virus was performed while worsening
[DOI] 10.7759/cureus.21867 PMC 바로가기 [Article Type] Obstetrics/Gynecology

An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees

자동화된 화학발광 면역분석(CLIA)은 COVID-19 환자와 백신 수혜자의 SARS-CoV-2 중화 항체 수준을 감지합니다.

Article

Published on 2022-02-012022-09-11
Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Analysing Antigen antigens automated can be used characteristic chemiluminescent immunoassay CLIA Concentration concentrations convalescent patient Coronavirus-2 COVID-19 patient cut-off value detect Diagnosis domain ectodomain Effectiveness evaluate evaluated groups half-life healthy individual indicated Infection linear mathematical mathematical model Mathematical models Microneutralization test MNT NAb titer NAb titers neutralizing antibody positive Protective protocol R 2 RBD receiver operating characteristic receiver operating characteristic curve respiratory SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccine sensitivity severe acute respiratory syndrome Coronavirus specificity tested Treatment Vaccine vaccinee vaccinees variable
[DOI] 10.1016/j.ijid.2021.12.316 PMC 바로가기 [Article Type] Article

SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people

SARS-CoV-2 mRNA 백신은 순진하고 이전에 감염된 사람들에게 강력한 특이적이고 교차 반응성인 IgG 및 불평등한 중화 항체를 유도합니다.

Article

Published on 2022-02-012022-09-11
Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Alpha alpha and delta variants antibody Antibody Response Complete coronavirus disease Coronavirus disease 2019 Coronavirus-2 correlates of protection COVID-19 Critical cross-reactive cross-reactive antibodies cross-reactive antibody delta variant Endemic first dose Frequency healthy individual human endemic coronavirus IgG individual individuals induce infected individual infected individuals Infection mRNA mRNA vaccine naïve individuals neutralization Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody response neutralizing antibody responses pandemic reference strain respiratory robust SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 spike SARS-CoV-2 variant SARS-CoV-2 variants seasonal coronavirus seasonal coronaviruses second dose serostatus serostatus determination Seven Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 strength Support understanding vaccination Vaccination strategy vaccine dose Variability variability in antibody response. variants
[DOI] 10.1016/j.celrep.2022.110336 PMC 바로가기 [Article Type] Article

Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR

COVID-19 환자의 진단 및 질병 중증도 예측의 잠재적 마커로서의 Endocan: 위음성 RT-PCR 환자를 위한 유망한 바이오마커

Original Article

Published on 2022-01-242022-09-10
Journal: Upsala Journal of Medical Sciences [Category] SARS, 바이오마커,

[키워드] assistant Biomarker Blood blood test can be used Clinical severity control group correlation COVID-19 COVID-19 case COVID-19 cases COVID-19 disease COVID-19 infection COVID-19 patient COVID-19 patients cut-off value determine Diagnosis diagnostic value disease severity endocan enrolled false false-negative healthy control healthy individual healthy individuals Inflammatory biomarker Laboratory laboratory findings marker no significant difference Patient patient group patient groups patients PCR tests polymerase positive correlation positive RT-PCR radiological Result reverse transcription reverse transcription polymerase change reaction RT-PCR RT-PCR test SARS-CoV-2 sensitivity serum significant difference significantly specificity the disease
[DOI] 10.48101/ujms.v127.8211 PMC 바로가기 [Article Type] Original Article

Estimation of SARS-CoV-2 Infection Fatality Rate by Age and Comorbidity Status Using Antibody Screening of Blood Donors During the COVID-19 Epidemic in Denmark

덴마크의 COVID-19 유행 기간 동안 헌혈자의 항체 스크리닝을 사용한 연령 및 동반이환 상태별 SARS-CoV-2 감염 사망률 추정

Article

Published on 2022-01-182022-09-12
Journal: The Journal of Infectious Diseases [Category] 진단,

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Research article

Published on 2022-01-142022-10-05
Journal: EClinicalMedicine [Category] 임상,

[키워드] 95% CI adverse event adverse events AEs AEsAdverse events anti-S IgG anti-SARS-CoV-2 antibody binding Citadel clinical development Clinical research collected Concentration conducted COVID-19 COVID-19 vaccine dose Dose escalation earth effective ELISA enrolled enrolment EudraCT facility finding Follow-up force funding gene of Interest geometric mean GOIgene of Interest healthy individual Humoral response IgG ELISA immunoblot immunogenic induce injection interval intramuscular Joseph Lipid Lipid nanoparticle LNP LNPlipid nanoparticle London low dose low dose vaccine Medical Research Council neutralisation neutralisation assays non-structural protein NSPnon-structural protein Open-label participant partner Phase I post-hoc raised ranged required RNA RNA vaccine Safe Safety saRNAself-amplifying RNA SARS-CoV-2 self-amplifying RNA sera Serious Adverse Event Seroconversion serological evidence Trial Trust vaccination Vaccine VEEVVenezuelan equine encephalitis virus Venezuelan equine encephalitis virus was measured was related wild type
[DOI] 10.1016/j.eclinm.2021.101262 [Article Type] Research article

Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers

노출되고 순진한 의료 종사자 집단에서 COVID-19 mRNA 백신에 대한 초기 항체 반응의 결정 요인

Clinical Trial

Published on 2022-01-012022-09-11
Journal: EBioMedicine [Category] 변종, 임상, 진단, 치료기술, 치료법,

[키워드] 95% CI Adults adverse events Affect allergy Alpha Analysis analyzed antibody Antibody avidity antibody levels Antibody Response Antigen antigens avidity Barcelona Beta BNT162b2 brand center Cohort Comorbidities Comorbidity COVID-19 COVID-19 mRNA vaccine Daniel Data collection days post-infection decision determinant development dose Effectiveness Efficacy European evaluated expected Factor Gamma had no Health care Health care worker health care workers healthcare worker healthy individual heterogeneity IgA IgG IgG and IgM IgG level IgG levels Immunity indicate Infectious disease Infectious diseases Influenza Innovation maintenance manuscript Moderna mRNA mRNA vaccination mRNA vaccines mRNA-1273 naïve neutralization neutralization capacity neutralizing capacity nucleocapsid omicron Pfizer/BioNTech preparation Program reagent receiving recommendation respond response responsiveness robust SARS-CoV-2 SARS-CoV-2 spike Science second dose seropositive Severo Ochoa shown Single-dose smoking Spanish state Study design Support supported symptomatic systemic adverse effect systemic adverse effects technology the preparation union vaccination vaccine doses vaccinees variant variants variants of concern wild-type
[DOI] 10.1016/j.ebiom.2021.103805 PMC 바로가기 [Article Type] Clinical Trial

Clinical Management of COVID-19 Patients – An Update

Review article

Published on 2022-01-012022-10-05
Journal: Seminars in nuclear medicine [Category] SARS, 치료제,

[키워드] anticoagulation antivirals be worn blood sample cause chest X-ray clinical Cognitive impairment Contact COVID-19 COVID-19 disease CT scan determine Diagnosis drug Dyspnea evaluated fatigue ground-glass opacity Health healthy individual Hospitalization hospitals imaging Immunocompromised patients include indications laboratory-confirmed Loss of Smell Mental Mild mild-to-moderate disease monoclonal antibody Mortality organ system outpatient clinic Oxygen therapy patchy Patient patients PCR physical plasma Population PPE receiving rehabilitation reported reported symptom SARS-CoV-2 RNA SARS-CoV-2 virus severe COVID-19 severity Steroids suspected patient Symptom tested therapy treated Treatment
[DOI] 10.1053/j.semnuclmed.2021.06.004 [Article Type] Review article

Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients

Article

Published on 2021-12-212022-10-29
Journal: Microorganisms [Category] COVID-19,

[키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody antibodies AZD1222 BNT162b2 booster cellular Cellular immune response Cohort convalescent patient coronavirus COVID-19 COVID-19 vaccination criterion detectable dialysis elicited healthy individual healthy individuals humoral IgG titer immune immune response immune system immunization Immunosuppression independent risk factor initial interferon-γ Kidney disease kidney transplant Linear regression model medication mRNA-1273 Patient patient subgroup performed protection quantified reactivity receiving recipient recipients response Retrospective analysis SARS-CoV-2 separated Seroconversion seroconversion rate serological significantly lower titer Transplant vaccination
[DOI] 10.3390/microorganisms10010004 PMC 바로가기 [Article Type] Article